2021年

≪英文≫

Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.

Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Ozaki Y, Tashiro Y, Uegaki M, Kojima T, Uchida J, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group.

Int J Urol. 2021 Sep 20. doi: 10.1111/iju.14686. Online ahead of print. PMID: 34545627

 

Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.

Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group.

(Kurahashi R is indicated in Acknowledgement.)

BJU Int. 2021 June 10. doi: 10.1111/bju.15510. Online ahead of print. PMID: 34110696

 

Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.

Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M.

Jpn J Clin Oncol. 2021;51(11):1656-1664.

 

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.

Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB Jr, Oudard S, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE; ACIS Investigators.

(Murakami Yoji is indicated in List of investigators/sites, Supplementary appendix.)

Lancet Oncol. 2021;22(11):1541-1559.

 

Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer.

Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S.

Clin Cancer Res. 2021;27(22):6164-6173.

 

t(6; 11) renal cell carcinoma. A case report successfully diagnosed by using fluorescence in situ hybridization.

Nishizawa H, Baba M, Furuya M, Kato I, Kurahashi R, Honda Y, Mikami Y, Nagashima Y, Eto M, Kamba T.

IJU Case Rep. 2021;4(6):375-378.

 

High T-cell infiltration in tumor tissue and younger age predict the response to pembrolizumab in recurrent urothelial cancer.

Anami T, Komohara Y, Miura Y, Yamanaka K, Kurahashi R, Segawa T, Motoshima T, Murakami Y, Yatsuda J,Yamaguchi T, Sugiyama Y, Jinnouchi Y, Kamba T.

Med Mol Morphol. 2021;54(4):316-323.

 

Surveillance of urachal abscess in the Kyushu-Okinawa area of Japan.

Tobu S, Udo K, Nishihara K, Miyajima S, Ando T, Onizuka C, Itesako T, Ashikari A, Hakariya T, Igawa T, Tanaka M, Shin T, Kamoto T, Nakagawa M, Saito S, Sakai H, Eto M, Kamba T, Fujimato N, Noguchi M.

Int J Urol. 2021;28(10):1008-1011.

 

Anti-cancer immune reaction and lymph node macrophage; a review from human and animal studies.

Komohara Y, Anami T, Asano K, Fujiwara Y, Yatsuda J, Kamba T.

Immuno. 2021;1(3):223-230.

 

Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.

Nakajima K, Mizokami A, Matsuyama H, Ichikawa T, Kaneko G, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A; PROSTAT-BSI Investigators.

Int J Urol. 2021 Sep;28(9):955-963.

 

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators.

(Murakami Yoji is indicated in List of Investigators, Supplementary Appendix.)

N Engl J Med. 2021;385(8):683-694.

 

HLA-DR and CD74 Expression and the Immune Microenvironment in Renal Cell Carcinoma.

Miura Y, Anami T, Yatsuda J, Motoshima T, Oka S, Suyama K, Kinowaki K, Urakami S, Kamba T, Komohara Y.

Anticancer Res. 2021;41(6):2841-2848.

 

Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.

Ito K, Kobayashi T, Kojima T, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Osaki Y, Tashiro Y, Uegaki M, Ogawa O, Kitamura H, Nishiyama H.

Cancer Med. 2021;10(10):3188-3196.

 

Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.

Kubota M, Kanno T, Inoue T, Yamasaki T, Okumura K, Ito K, Yamada H, Fujii M, Shimizu Y, Yatsuda J, Moroi S, Shichiri Y, Akao T, Sawada A, Saito R, Kobayashi T, Kawakita M, Ogawa O.

Int J Urol. 2021;28(6):656-664.

 

Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study).

Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kabu K, Tajima Y, Oya M.

Jpn J Clin Oncol. 2021;51(6):966-975.

 

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.

Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Ogawa O, Kitamura H, Nishiyama H; Japan Urological Oncology Group.

(Kumamoto University Department of Urology participates in JUOG and provided the data to this study.)

Cancer Sci. 2021;112(2):760-773.

 

Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.

Imamura R, Kitagawa S, Kubo T, Irie A, Kariu T, Yoneda M, Kamba T, Imamura T.

Prostate. 2021;81(3):147-156.

 

Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer.

Inokuchi J, Kuroiwa K, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Takenaka A, Fujimoto K, Yamaguchi R, Habuchi T, Hashine K, Mizusawa J, Eba J, Naito S; Urologic Oncology Study Group of the Japan Clinical Onocology Group (JCOG).

(Kamba T is indicated in Acknowledgement.)

Int J Urol. 2021;28(2):208-214.

 

Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.

Sakamoto H, Yamasaki T, Sumiyoshi T, Takeda M, Shibasaki N, Utsunomiya N, Arakaki R, Akamatsu S, Kobayashi T, Inoue T, Kamba T, Nakamura E, Ogawa O.

Cancer Med. 2021;10(1):119-134.

 

Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma.

Yamamoto Y, Yatsuda J, Shimokawa M, Fuji N, Aoki A, Sakano S, Yamamoto M, Suga A, Tei Y, Yoshihiro S, Kitahara S, Nagao K, Takai K, Kamiryo Y, Akao J, Yamaguchi S, Oba K, Shimabukuro T, Matsumoto H, Kamba T, Matsuyama H.

Int J Clin Oncol. 2021;26(1):169-177.

 

≪和文≫

集学的治療により完全寛解を得た難治性非セミノーマ精巣腫瘍(後腹膜リンパ節,肝,肺,脳転移)の1例

山中広太郎,山口隆大,倉橋竜磨,元島崇信,村上洋嗣,矢津田旬二,杉山豊,西一彦,神波大己

泌尿紀要. 2021;67(9):433-437.